BR112013022017A2 - formulação farmacêutica, comprimido, e, método para produzir uma formulação farmacêutica - Google Patents

formulação farmacêutica, comprimido, e, método para produzir uma formulação farmacêutica

Info

Publication number
BR112013022017A2
BR112013022017A2 BR112013022017A BR112013022017A BR112013022017A2 BR 112013022017 A2 BR112013022017 A2 BR 112013022017A2 BR 112013022017 A BR112013022017 A BR 112013022017A BR 112013022017 A BR112013022017 A BR 112013022017A BR 112013022017 A2 BR112013022017 A2 BR 112013022017A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
weight
tablet
producing
pharmaceutical
Prior art date
Application number
BR112013022017A
Other languages
English (en)
Inventor
Karl Kolter
Michael Schönherr
Sandra Kruse
Silke Gebert
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se filed Critical Basf Se
Publication of BR112013022017A2 publication Critical patent/BR112013022017A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

formulação farmacêutica, comprimido, e, método para produzir uma formulação farmacêutica formulação farmacêutica sob a forma de grânulos que a) 60% a 96% em peso de açúcares não formadores de película ou alcoóis de açúcar, b) 1% a 10% em peso de açúcares formadores de ou alcoóis de açúcar, c) 3% a 25% em peso de agentes de desintegração, d) 0% a 10% em peso de polímeros formadores de película,insolúveis em água, e) 0% a 15% em peso, de outros excipientes farmacêuticos habituais, a soma dos componentes a) a e) sendo 100% em peso.
BR112013022017A 2011-03-09 2012-03-06 formulação farmacêutica, comprimido, e, método para produzir uma formulação farmacêutica BR112013022017A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11157458 2011-03-09
PCT/EP2012/053771 WO2012119997A1 (de) 2011-03-09 2012-03-06 Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten

Publications (1)

Publication Number Publication Date
BR112013022017A2 true BR112013022017A2 (pt) 2016-11-29

Family

ID=45787220

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013022017A BR112013022017A2 (pt) 2011-03-09 2012-03-06 formulação farmacêutica, comprimido, e, método para produzir uma formulação farmacêutica

Country Status (5)

Country Link
EP (1) EP2683365A1 (pt)
JP (1) JP2014507454A (pt)
CN (1) CN103415284B (pt)
BR (1) BR112013022017A2 (pt)
WO (1) WO2012119997A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3203975A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
CA3216359A1 (en) 2021-04-07 2022-10-13 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
JP2024542726A (ja) * 2021-12-02 2024-11-15 ビーエーエスエフ ソシエタス・ヨーロピア 直接打錠補助組成物
AU2024353375A1 (en) 2023-09-29 2026-04-09 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19615418A1 (de) * 1996-04-22 1997-10-23 Merck Patent Gmbh Polyol-Zusammensetzung
JPH1020380A (ja) * 1996-07-05 1998-01-23 Minolta Co Ltd カメラ
EP0839526A3 (en) 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
FR2781152B1 (fr) 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
US20020071864A1 (en) 1999-03-25 2002-06-13 Yuhan Corporation Rapidly disintegrable tablet for oral administration
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
JP2004265216A (ja) 2003-03-03 2004-09-24 Seiko Epson Corp 印刷装置、受信装置、中継装置、印刷システムおよび印刷方法
US8647668B2 (en) * 2003-10-15 2014-02-11 Fuji Chemical Industry Co., Ltd. Tablet quickly disintegrating in oral cavity
CN1732905A (zh) * 2004-08-09 2006-02-15 赵力 可直接压片的木糖醇颗粒及其制法
CN1686089B (zh) * 2005-05-08 2010-08-18 北京健健康康生物技术有限公司 一种可直接压片的木糖醇颗粒及其制备方法
CN101360480B (zh) * 2005-12-21 2015-04-08 巴斯夫欧洲公司 用于制备快速崩解片剂的药物配制剂
US8425935B2 (en) * 2005-12-21 2013-04-23 Basf Se Pharmaceutical formulation for producing rapidly disintegrating tablets
BRPI0811303A2 (pt) * 2007-05-08 2015-01-27 Hercules Inc Formulação de comprimido de desintegranção rápida robusta
CN102046147B (zh) * 2007-06-06 2013-03-20 巴斯夫欧洲公司 用于制备快速崩解的片剂的药物配制剂

Also Published As

Publication number Publication date
CN103415284A (zh) 2013-11-27
EP2683365A1 (de) 2014-01-15
WO2012119997A1 (de) 2012-09-13
JP2014507454A (ja) 2014-03-27
CN103415284B (zh) 2016-12-07

Similar Documents

Publication Publication Date Title
MX346224B (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
GT201400069A (es) Composiciones farmaceuticas
CL2014003566A1 (es) Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson.
JO3091B1 (ar) مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها
CR20130598A (es) Composiciones de nucleasa terapéuticas y métodos
UY35210A (es) Inhibidores de autotaxina
HK1218621A1 (zh) 用於治疗慢性炎症和炎性疾病的组合物及方法
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
BR112014024903A2 (pt) anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos
BR112015020389A8 (pt) compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos
CL2014002324A1 (es) Metodo para lentificar el avance, demorar o tratar la prediabetes en un paciente con sobrepeso u obeso que comprende la administracion de empagliflozina y uno o varios fármacos antiobesidad y composición farmacéutica que comprende a dichos farmacos.
BR112018010018A2 (pt) moduladores de ror-gama
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
BR112013024423A2 (pt) detecção de doença em plantas
BRPI0812064B8 (pt) formulação farmacêutica na forma de aglomerados, comprimidos, e, processo para a produção de uma formulação farmacêutica
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
EA201590161A1 (ru) Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
BR112014029286A2 (pt) composição cosmética sólida, processo para sua produção, produto e método cosmético
CU20140037A7 (es) Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
BR112013022017A2 (pt) formulação farmacêutica, comprimido, e, método para produzir uma formulação farmacêutica
BR112013008749A2 (pt) análogos de ciclosporina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 7A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2504 DE 02/01/2019.